Navigation Links
OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY
Date:5/12/2008

WILMINGTON, Mass., May 12 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has enrolled its first patient in the SONIC II REGISTRY. SONIC II is a prospective, multi-center U.S. registry study of the company's OmniWave(TM) Endovascular System (OES) in patients undergoing percutaneous mechanical thrombectomy for acute limb ischemia (ALI). All patients enrolled in the SONIC II REGISTRY are scheduled for follow-up at 30 days, 6 months, and 1 year following the OmniWave procedure. The first patient was enrolled at the Midwest Institute for Minimally Invasive Therapies (MIMIT) in Chicago, IL, by Paramjit (Romi) Chopra, M.D.

"The SONIC II REGISTRY is an important collaboration between OmniSonics and healthcare professionals treating acute limb ischemia to bring innovative treatments to patients suffering from such a disabling disease. We are proud to be in a position to contribute clinical data to such a valuable study," said Paramjit (Romi) Chopra M.D., Director for the MIMIT.

Richard Ganz, President and CEO of OmniSonics Medical Technologies, said, "The initiation of the SONIC II REGISTRY is an important strategic development in OmniSonics' continuation of a strong clinical program to support the OmniWave Endovascular System as a therapy for treating patients with ALI. We are excited about the enthusiasm that the physician community has expressed for this technology and its future potential applications in clinical practice."

In September 2007, OmniSonics received clearance from the Food and Drug Administration (FDA) to market its catheter based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature. OmniSonics is also currently collecting data in the SONIC I REGISTRY of the company's OmniWave Endovascular System in patients undergoing percutaneous mechanical thrombectomy of acute deep vein thrombosis (DVT).

The OmniWave Endovascular System is based on patented OmniWave technology, the first minimally invasive catheter-based technology that delivers low-power, transverse ultrasonic energy to remove thrombus quickly, safely, and effectively. Thrombus (also known as a blood clot) occurs in a number of conditions including deep vein thrombosis (DVT) and acute limb ischemia (ALI). DVT affects approximately 2 million people in the U.S. every year, and acute limb ischemia affects over 250,000 people in the U.S. every year.

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular disease. The Company's products are based on its patented OmniWave technology, the first technology capable of delivering low-power ultrasonic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave technology is designed to have broad applications in vascular disease.

Contact: Len Farris

Vice President, Marketing

(978) 657-9980 x501

lfarris@omnisonics.com


'/>"/>
SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
(Date:2/18/2017)... ... 18, 2017 , ... A new directory from the Senior ... easily connect elderly veterans of America's armed forces to a range of senior ... material on this year's increase in the Veterans Pension with Aid & Attendance ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As ... showcase its anatomic and molecular pathology workflow solution, as well as its new ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics ... of diagnostic information services, today announced that it has ... for 2017 by Fortune. The annual ... companies in the "Health Care: Pharmacy and Other Services" ... diagnostic information services company to attain the designation. This ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company, today announced that executive management will participate ... be held February 22-23, 2017. Adrian Adams , ... Company at 1:35 p.m. local time on Wednesday, February ... archive for the event may be accessed from the ...
Breaking Medicine Technology: